Vertex 611-110

Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

 

Purpose: Study with Combination Therapy Ivacaftor and VX-661 for subjects older than 12 years of age with Cystic Fibrosis genotype heterozygote.

Study status: Study will only accept subjects from VERTEX 661-108. 

Sponsor: Vertex Pharmaceuticals

Principal Investigator: Cori Daines, MD

Contact Information:

Osmara Y. Molina de Rodriguez, MS

Cell: (520) 891-6767 or Office: (520) 626-3910

Study Status: 
Currently Enrolling